AI Collaboration and Licensing: 2019-2025 Analysis

Published Date : 19/06/2025 

This report provides a detailed analysis of 959 artificial intelligence deals from 2019 to 2025, including financial terms and contract documents, offering insights into the AI dealmaking trends in the biopharma industry. 

Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The 'Artificial Intelligence (AI) Collaboration and Licensing Deals 2019-2025' has been added to ResearchAndMarkets.com's offering. This report is a comprehensive listing of 959 artificial intelligence deals announced since 2019, including financial terms where available, and links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals, offering an orientation of artificial intelligence dealmaking.

The initial chapters of the report offer an orientation of artificial intelligence dealmaking. It begins with an introduction, followed by an overview of the trends in AI dealmaking since 2019. The chapters then highlight leading AI deals, list the top 25 most active companies in AI dealmaking, and provide detailed reviews of AI deals and partnering agreements, organized by specific AI technology type and available contract documents.

The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence deal-making since 2019. A comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

- Understand deal trends since 2019

- Browse artificial intelligence collaboration and licensing deals

- Benchmark analysis - identify market value of transactions

- Financial terms - upfront, milestone, royalties

- Directory of deals by company A-Z, deal type, and therapy area

- Leading deals by value

- Most active dealmakers

- Identify assets and deal terms for each transaction

- Access contract documents - insights into deal structures

- Due diligence - assess the suitability of your proposed deal terms for partner companies

- Save hundreds of hours of research time

Artificial Intelligence (AI) Collaboration and Licensing Deals includes:

- Trends in artificial intelligence dealmaking in the biopharma industry

- Directory of artificial intelligence deal records covering pharmaceutical and biotechnology

- The leading artificial intelligence deals by value

- Most active artificial intelligence licensing dealmakers

Analyzing contract agreements allows due diligence of:

- What are the precise rights granted or optioned?

- What is actually granted by the agreement to the partner company?

- What exclusivity is granted?

- What is the payment structure for the deal?

- How are sales and payments audited?

- What is the deal term?

- How are the key terms of the agreement defined?

- How are IPRs handled and owned?

- Who is responsible for commercialization?

- Who is responsible for development, supply, and manufacture?

- How is confidentiality and publication managed?

- How are disputes to be resolved?

- Under what conditions can the deal be terminated?

- What happens when there is a change of ownership?

- What sublicensing and subcontracting provisions have been agreed?

- Which boilerplate clauses does the company insist upon?

- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

- Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

- Executive Summary

- Chapter 1 - Introduction

- Chapter 2 - Trends in artificial intelligence dealmaking

- 2.1. Introduction

- 2.2. Artificial intelligence deals over the years

- 2.3. Most active artificial intelligence dealmakers

- 2.4. Artificial intelligence deals by deal type

- 2.5. Artificial intelligence deals by therapy area

- 2.6. Artificial intelligence deals by industry sector

- 2.7. Deal terms for artificial intelligence deals

- 2.7.1 Artificial intelligence deals headline values

- 2.7.2 Artificial intelligence deal upfront payments

- 2.7.3 Artificial intelligence deal milestone payments

- 2.7.4 Artificial intelligence royalty rates

- Chapter 3 - Leading artificial intelligence deals

- 3.1. Introduction

- 3.2. Top artificial intelligence deals by value

- Chapter 4 - Most active artificial intelligence dealmakers

- 4.1. Introduction

- 4.2. Most active artificial intelligence dealmakers

- 4.3. Most active artificial intelligence deals company profiles

- Chapter 5 - Artificial intelligence contracts dealmaking directory

- 5.1. Introduction

- 5.2. Artificial intelligence contracts dealmaking directory

- Chapter 6 - Artificial intelligence dealmaking by technology type

- Deal directory

- Deal directory - Artificial intelligence deals by company A-Z

- Deal directory - Artificial intelligence deals by deal type

- Deal directory - Artificial intelligence deals by therapy area

- Deal type definitions

Companies Featured:

- 3M

- ACT Therapeutics

- AdventHealth

- AbbVie

- Amgen

- Apple Inc.

- Alphabet Inc.

- Amazon Web Services

- General Electric

- IBM

- Microsoft

- Oracle

- Pfizer

- Tata Consultancy Services

- JP Morgan Chase

- Goldman Sachs

- Boeing

- Hewlett Packard Enterprise

- Procter & Gamble

- Johnson & Johnson

- Delta Air Lines

- Ford Motor Company

- Facebook

- NVIDIA Corporation

- Cisco Systems

- Intel Corporation

- Verizon Communications

- Coca-Cola Company

- Samsung Electronics

- Tesla, Inc.

- ExxonMobil

- Walmart

- PepsiCo

- Disney

- Adobe Systems

- Salesforce

- Nike

- Unilever

- Red Hat

- Siemens AG

- American Express

- Berkshire Hathaway

- Starbucks

- Alphabet Inc.

- Arm Holdings

- LinkedIn

- Airbnb

- Netflix

- Spotify

- SpaceX

- Uber Technologies

For more information about this report visit https://www.researchandmarkets.com/r/rzi6nb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products, and the latest trends. 

Frequently Asked Questions (FAQS): 

Q: What is the main focus of the 'Artificial Intelligence (AI) Collaboration and Licensing Deals 2019-2025' report?

A: The report focuses on providing a comprehensive analysis of 959 artificial intelligence deals from 2019 to 2025, including financial terms, deal types, and contract documents, to help understand AI dealmaking trends in the biopharma industry.

Q: Who are the leading companies in AI dealmaking according to the report?

A: The report lists the top 25 most active companies in AI dealmaking, including major players like NVIDIA Corporation, Cisco Systems, Intel Corporation, and many others.

Q: What kind of deals are covered in the report?

A: The report covers collaboration, development, research, and licensing deals in the artificial intelligence sector, providing detailed reviews and contract documents where available.

Q: How can the report be used for due diligence?

A: The report allows due diligence by providing insights into the precise rights granted, payment structures, deal terms, and key provisions of AI deals, helping assess the suitability of proposed deal terms for partner companies.

Q: What additional resources are provided in the report?

A: The report includes a comprehensive deal directory organized by company A-Z, deal type, and therapy area, as well as numerous tables and figures illustrating trends and activities in AI deal-making since 2019. 

More Related Topics :